News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,044 Results
Type
Article (39746)
Company Profile (248)
Press Release (660050)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204190)
Career Advice (2008)
Deals (35424)
Drug Delivery (95)
Drug Development (81061)
Employer Resources (172)
FDA (16189)
Job Trends (14864)
News (345241)
Policy (32548)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49446)
ALS (95)
Alzheimer's disease (1383)
Antibody-drug conjugate (ADC) (132)
Approvals (16188)
Artificial intelligence (264)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (176)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (292)
Cancer (2320)
Cardiovascular disease (179)
Career advice (1677)
Career pathing (30)
CAR-T (155)
Cell therapy (436)
Cervical cancer (20)
Clinical research (66099)
Collaboration (858)
Company closure (2)
Compensation (569)
Complete response letters (19)
COVID-19 (2590)
CRISPR (41)
C-suite (250)
Cystic fibrosis (102)
Data (2337)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6382)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (103)
Drug shortages (25)
Duchenne muscular dystrophy (96)
Earnings (87066)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112663)
Executive appointments (741)
FDA (17572)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (771)
Gene editing (109)
Generative AI (20)
Gene therapy (314)
GLP-1 (720)
Government (4431)
Grass and pollen (4)
Guidances (162)
Healthcare (18820)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (125)
Indications (29)
Infectious disease (2735)
Inflammatory bowel disease (144)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (98)
Interviews (312)
IPO (16527)
IRA (40)
Job creations (3633)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7911)
Liver cancer (76)
Lung cancer (325)
Lymphoma (157)
Machine learning (9)
Management (58)
Manufacturing (328)
MASH (77)
Medical device (13384)
Medtech (13389)
Mergers & acquisitions (19471)
Metabolic disorders (707)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (94)
Neuropsychiatric disorders (27)
Neuroscience (1941)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (40)
Obesity (371)
Opinion (206)
Ovarian cancer (81)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (154)
Partnered (22)
Patents (245)
Patient recruitment (116)
Peanut (46)
People (57345)
Pharmaceutical (63)
Pharmacy benefit managers (19)
Phase I (20593)
Phase II (29113)
Phase III (21682)
Pipeline (1385)
Policy (147)
Postmarket research (2563)
Preclinical (8761)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (384)
Real estate (5907)
Recruiting (65)
Regulatory (22331)
Reports (47)
Research institute (2321)
Resumes & cover letters (349)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (72)
Series A (131)
Series B (90)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3580)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (50)
The Weekly (30)
Vaccines (699)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (173)
Last 7 days (954)
Last 30 days (3190)
Last 365 days (32539)
2025 (11925)
2024 (35222)
2023 (40079)
2022 (51173)
2021 (55711)
2020 (54084)
2019 (46538)
2018 (35022)
2017 (32112)
2016 (31481)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37887)
Australia (6193)
California (6422)
Canada (2065)
China (540)
Colorado (274)
Connecticut (281)
Delaware (158)
Europe (81418)
Florida (957)
Georgia (215)
Idaho (57)
Illinois (547)
India (25)
Indiana (323)
Iowa (11)
Japan (172)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (922)
Massachusetts (4772)
Michigan (226)
Minnesota (404)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1798)
New Mexico (28)
New York (1807)
North Carolina (990)
North Dakota (8)
Northern California (2837)
Ohio (210)
Oklahoma (14)
Oregon (34)
Pennsylvania (1429)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (26)
South Dakota (1)
Southern California (2411)
Tennessee (106)
Texas (951)
United States (24051)
Utah (188)
Virginia (151)
Washington D.C. (64)
Washington State (566)
West Virginia (3)
Wisconsin (56)
700,044 Results for "fibrogen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
AstraZeneca Buys FibroGen’s China Unit for $160M as Probes Continue
A year ago, AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.
February 20, 2025
·
2 min read
·
Tristan Manalac
Press Releases
FibroGen to Report First Quarter 2025 Financial Results
May 6, 2025
·
1 min read
Press Releases
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
·
11 min read
Press Releases
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million
February 20, 2025
·
5 min read
Press Releases
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
April 3, 2025
·
1 min read
Press Releases
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
March 17, 2025
·
11 min read
Press Releases
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
March 3, 2025
·
1 min read
Biotech Bay
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
FibroGen, Inc. (NASDAQ: FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron’s anti-PD-1 therapy, LIBTAYO® (cemiplimab), in patients with solid tumors.
June 3, 2024
·
5 min read
Layoffs
FibroGen to Lay Off 127 Workers in San Francisco
FibroGen expects its headcount reduction, which is tied to eliminating 75% of its U.S. workforce, to be mostly complete by the end of the first quarter of 2025.
August 12, 2024
·
1 min read
·
Angela Gabriel
Biotech Bay
FibroGen to Participate in Upcoming May 2024 Investor Conferences
FibroGen, Inc. announced that the company’s management will participate in the following investor conferences.
May 7, 2024
·
1 min read
1 of 70,005
Next
